Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MINISO Group Holding Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while MINISO Group Holding Ltd trades at $11.47 (market cap $3.51B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 11.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.65% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MNSO | |
|---|---|---|
Market Cap | $39.89B | $3.51B |
Sector | Health | Technology |
52-Week High | $491.22 | $26.63 |
52-Week Low | $278.09 | $11.30 |
Enterprise Value | $38.15B | $4.17B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
MNSO trades at $11.79, up 2.79% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating expectations with EPS of $0.591, and announced a HK$2 billion share repurchase program on June 29, 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 12, indicating potential undervaluation.
The outlook is mixed: analyst consensus is 75% buy with growth potential from overseas expansion, but risks include margin compression and recent earnings misses. The stock's current price near the lower end of its 52-week range suggests caution amid bearish technical trends, though fundamentals support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
